AAV-FGF21 gene therapy

AAV-FGF21 gene therapy has no effect on liver metabolic function in mice.

“High levels of FGF21 alone in aged mice is not sufficient to improve liver or muscle functions.”

Animalsfat-directed rAAV-FGF21 vector7-monthfemales

Long-term effects of a fat-directed FGF21 gene therapy in aged female mice

Gene therapy·12 Sep 2023

AAV-FGF21 gene therapy has no effect on muscle function in mice.

“However, those changes were not translated into benefits on muscle function and did not affect metabolic function of liver.”

Animalsfat-directed rAAV-FGF21 vector7-monthfemales

Long-term effects of a fat-directed FGF21 gene therapy in aged female mice

Gene therapy·12 Sep 2023

AAV-FGF21 gene therapy increases energy expenditure in mice.

“increased relative lean mass and energy expenditure associated with almost 100 folds higher serum level of FGF21”

Animalsfat-directed rAAV-FGF21 vector7-monthfemales

Long-term effects of a fat-directed FGF21 gene therapy in aged female mice

Gene therapy·12 Sep 2023

AAV-FGF21 gene therapy decreases adiposity in mice.

“FGF21 treatment reduced adiposity and increased relative lean mass and energy expenditure”

Animalsfat-directed rAAV-FGF21 vector7-monthfemales

Long-term effects of a fat-directed FGF21 gene therapy in aged female mice

Gene therapy·12 Sep 2023

AAV-FGF21 gene therapy decreases body weight in mice.

“Animals with FGF21 treatment displayed a steady, significant lower body weight over 7-month of the study compared to age-matched control mice.”

Animalsfat-directed rAAV-FGF21 vector7-monthfemales

Long-term effects of a fat-directed FGF21 gene therapy in aged female mice

Gene therapy·12 Sep 2023